Cheez-It Drops a New Flavor Inspired by Wendy's Fan-Favorite Menu Item
Wendy's and Cheez-It teamed up to launch Cheez-It x Wendy's Baconator crackers, debuting in stores this July
The crackers blend the cheesy crunch of a Cheez-It cracker with the savory flavor of Wendy's Baconator
A bundle with a Frosty keychain will be sold on CheezIt.com; customers can scan a QR code on the box for $2 off a Baconator in the Wendy's app.Wendy's is adding to the Baconator universe with its new product partnership.
On Tuesday, June 10, the fast food giant announced its latest partnership with Cheez-It to bring together two flavors into one cheesy, portable snack: Cheez-It x Wendy's Baconator crackers.
The limited-edition collaboration delivers the classic crunch of a Cheez-It cracker, made with 100% real cheese, combined with the savory taste of the Baconator burger, including hints of Applewood smoked bacon.
'With Wendy's, we found the perfect partner to create something completely unexpected – a snack that brings the craveable flavor of the Baconator to the cracker aisle in a way only Cheez-It can,' Wendy's said in a press release.
The Cheez-It x Wendy's Baconator cracker will be available in stores this July. The product can also be purchased in a bundle exclusively on CheezIt.com, which includes a Wendy's Frosty keychain tag. To receive free shipping, customers can use the code CHEEZBURGER.
'We took our famous Baconator – a burger known for its irresistible, beefy, bacon-loaded flavor – and reimagined it with the unmistakable cheesy crunch of Cheez-It," Wendy's said.
Customers can also scan the QR code on the back of their Cheez-It box to unlock additional fun in the Wendy's app, including $2 off a Baconator sandwich on a purchase made in the app.
The partnership comes just in time for Wendy's lovers to make their burger faves at home.
Wendy's just announced that now its signature burgers and double-smoked bacon will be available in grocery stores.
"Currently, Wendy's fans in some select markets can pick up double smoked bacon at their local King Soopers or Kroger. Wendy's fans can enjoy our famous bacon in our restaurants and at home," the fast food chain said.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced preliminary positive data from the first cohort of the Phase 1/2 Audiogene clinical trial evaluating the low dose of SENS-501, the Company's gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. The second cohort at a higher dose is ongoing and recruitment is close to being completed. The results from all patients dosed to date (5) confirm that SENS-501 and the corresponding surgical procedure are well tolerated by all participating infants and toddlers (aged 6 to 31 months and naive of cochlear implants at the time of the injection, as per study protocol) having received a gene therapy injection. Intracochlear administration of SENS-501 was uneventful, and no serious adverse events or serious side effects were reported. Three patients were enrolled into Cohort 1 and received a low dose of SENS-501 of 1.5 E 11 vg/vector/ear, corresponding to the minimally effective dose in preclinical studies. The primary objective is to assess the safety and feasibility of the intra-cochlear administration of SENS-501. In Cohort 1, early signs of hearing improvement were observed in Patient 3, aged 11 months at the time of injection. The clinical response observed in Patient 3 was evaluated using standard hearing tests carried out by the investigators (Auditory Brainstem Response ABR, Pure Tone Audiometry PTA, and Patient (Parents) Reported Outcomes PROs). Three-month data from the Patient 3 include: Positive ABR responses at two frequencies, with the best frequency reaching 70 dB. Improvement of hearing levels across two speech frequencies with best frequency reaching 90 dB level, per PTA. Meaningful changes in responses to sounds and voices as reported by the parents with an IT-MAIS score increase of 16 points (145% relative improvement from baseline), and met expected auditory milestones based on an age-based parent questionnaire and according to the patient's age (LittlEARS). The recruitment in Cohort 2, utilizing a second and higher dose level, is nearly complete. The Company plans to provide the next update when Cohort 2 data have reached sufficient maturity to determine next steps for the program. Professor Catherine Birman, ENT surgeon, otolaryngologist, and Senior Staff Specialist at the Children's Hospital at Westmead, Australia, commented: "I'm thrilled to report the preliminary Cohort 1 data of SENS-501 in the first infants and toddlers treated with this highly innovative therapy. Treatment with SENS-501 had a good safety profile and the onset of early auditory responses observed in Patient 3 of the first cohort is very encouraging, especially given the very low dose of vector injected, which is primarily intended at assessing the safety of the therapeutic and of the intracochlear surgical procedure. I look forward to Patient 3's next visit and continuing the Audiogene study with the second cohort to assess a higher dose of SENS-501. Treating children under 31 months of age and naive of cochlear implants is a much-needed undertaking, as restoring hearing in the first three years of childhood has the potential to result in de-novo language acquisition. We thank Sensorion for their commitment to this patient population.' The Phase 1/2 clinical trial Audiogene ( ID: NCT06370351), developed in the frame of the strategic partnership with the Institut Pasteur and led by Professor Natalie Loundon, Coordinating Investigator, M.D., Director of the Center for Research in Pediatric Audiology, Pediatric Otolaryngologist and Head and Neck Surgeon, Necker Enfants Malades, AP-HP, in Paris, France, aims to evaluate the safety and efficacy of an intra-cochlear injection of SENS-501 for the treatment of OTOF gene-induced hearing loss in paediatric patients aged 6 to 31 months and naive of cochlear implants at the time of the gene therapy treatment. Audiogene consists of a dose-escalation part, comprising two cohorts of three patients each, assessing a low dose of SENS-501 in Cohort 1 (1.5 E 11 vg/vector/ear) and a higher dose of SENS-501 in Cohort 2 (4.5 E 11 vg/vector/ear). The dose-escalation part will be followed by a dose-expansion cohort at the selected dose. While safety is the primary endpoint of the dose escalation study, Auditory Brainstem Response, twelve months following the injection, will be the primary endpoint for the dose expansion part. Audiogene is the first gene therapy clinical trial addressing a unique homogeneous population of infants and toddlers (aged 6 to 31 months and naive of cochlear implants at the time of the gene therapy injection). Addressing this young patient population aims at maximizing the chances of these infants and toddlers to acquire language (below three years old, when brain plasticity is optimal). Furthermore, and uniquely to Audiogene's gene therapy program, all enrolled patients should not have current or previous cochlear implantation in the treated or contralateral ear, allowing to best document the contribution of the gene therapy in speech development. About SENS-501 SENS-501 (OTOF-GT) is an innovative gene therapy program developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. This gene plays a key role in the transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. When this gene is defective, affected individuals are born with severe to profound hearing loss. The aim of SENS-501 (OTOF-GT) is to restore hearing by introducing a functional copy of the OTOF gene directly into hair cells via viral vector technology (AAV). This therapy aims to restore the normal process of converting sound into electrical signals, enabling patients to regain their hearing ability. Currently in the clinical research phase, this gene therapy program represents significant hope for families affected by this rare form of genetic deafness. SENS-501 (OTOF-GT) embodies a commitment to scientific innovation in the field of hearing, with the potential to dramatically improve the quality of life of patients suffering from genetic deafness. This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l'Audition. The project is partially financed by the French National Research Agency, through the 'investing for the future' program (ref: ANR-18-RHUS-0007). The OTOF gene targeted by the Audiogene trial was discovered in 1999 at the Institut Pasteur, by Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Pasteur Institute), who also unraveled the pathophysiology of the corresponding deafness (DFNB9). About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Forbes
18 hours ago
- Forbes
What Every Business Can Learn From Great Product Innovators
Peter Karlson is the founder of NeuEon, a company focused on business and technology transformation. Many traditional companies in sectors like distribution, manufacturing and insurance are taking a hard look at their vendor and technology stacks to see if they can do better. From a CIO perspective, outsourcing elements of IT infrastructure is often a smart move—especially for commoditized functions like communications and collaboration platforms. Consider how common it once was to host in-house email servers; today, migration to cloud-based solutions is the norm. But there's a catch. How Modern Innovation Techniques Add Value I recently spoke with a company that had been an early adopter of an AI tool meant to streamline workflows and save on labor costs. Now, that cost savings has flipped into a major budget line item—approaching seven figures annually. Their comment? 'We should build it ourselves.' That instinct makes sense—but it's not so simple, especially for companies operating with legacy IT people, processes and platforms. It takes a cultural shift to begin thinking like an innovation factory rather than a traditional factory. There's a lot to learn from how technology companies continuously innovate and deliver customer-focused products. When Outsourcing Starts To Cost Too Much In many organizations, internal IT teams still use an outdated "MIS" mindset—where the same people who build the systems also run them, and all the changes must go through them. This gatekeeping stifles innovation and delays the deployment of business-critical solutions. The opposite approach can be just as problematic: The business purchases a slew of off-the-shelf tools and either dumps integration on IT or leaves them siloed, requiring manual data transfers. Lessons From The Tech Industry When new leadership steps in, they often face massive project backlogs and multiyear road maps to deliver key functionality. To counter this, some forward-thinking leaders are launching innovation groups separate from the main IT function. These dedicated teams operate with the agility that today's business environment demands. Key Questions To Gauge Readiness The first step is to understand how your internal teams build solutions today. Ask yourself a few leading questions like: • Are they consistently delivering value? • Do they have a customer-centric culture? • Are they using modern tools and techniques? If the answer to any of these is 'no,' you likely need to prioritize building an innovation culture before you try to deliver innovative products. Building A Customer-Centric Innovation Culture Traditional IT departments often focus on 'keeping the lights on.' That only works if your business doesn't face frequent change. But change is the new constant—competition improves, customer needs shift and costs rise. Your systems must evolve accordingly. To meet this demand, companies need a mindset shift—one that mirrors how technology companies operate. With a business agility focus, you can identify change, fund it appropriately and deliver results faster than competitors, without sacrificing profit or market share. Assessing Your Innovation Assets Start by evaluating the people responsible for developing solutions, their processes and the quality of their output. Review your team's backgrounds, education and experience. Go a step further: Assess their personality traits like curiosity, creativity and risk tolerance. Personality traits shape how your team innovates and collaborates. Next, look at how they work. Do they use waterfall, agile or hybrid methodologies? Who translates business needs into concrete solutions? How quickly do they build, test and deploy solutions? Finally, assess the outcome. Does it solve real problems? Is the interface intuitive? Is the system fast? And ultimately, do your users enjoy using it? The Road Ahead This is just the beginning of the innovation journey. In future articles, I'll explore and provide specific techniques that companies can use to accelerate corporate innovation, including the following: • Generating and capturing new ideas • Evaluating feasibility, desirability and viability • Developing business cases for high-potential concepts • Using agile, iterative testing to validate solutions that stakeholders will value Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Business Wire
a day ago
- Business Wire
From Waste to Strategic Metals: Circular Materials Achieves First Industrial-Scale Recoveries Under the Critical Raw Materials Act
PADUA, Italy--(BUSINESS WIRE)--Circular Materials announces two major milestones under the Critical Raw Materials Act: the recovery from industrial wastewater of the first kilogram of ruthenium and the first ton of nickel, preventing the release of heavy metals into the environment. These results were secured through strong collaborations with two leading companies in surface treatments: LEM, core company of the LEM INDUSTRIES Group, specialized in the luxury sector, and Argos Surface Technologies Group, a leader in industrial coatings. We recover what the world needs most: Circular Materials delivers first industrial-scale metal recoveries. This success comes just a few months after the European Commission recognized Recover-IT as a strategic project, confirming the pivotal role of Circular Materials in securing critical raw material supplies, increasing recycling, and reducing the EU's dependence on imports. Ruthenium and Nickel: crucial metals for a sustainable future Ruthenium, a noble metal from the platinum group, is essential for cutting-edge sectors such as advanced electronics, green hydrogen production, fine chemicals, fuel cells, and luxury goods. Nickel, on the other hand, is a critical element, essential in advanced steels and lithium batteries —pillars of the energy transition. Circular Materials' proprietary SWaP (Supercritical Water Precipitation) technology delivers exceptional effectiveness and versatility to recover precious and industrially intensive metals. A revolutionary environmental impact: carbon negative and beyond Life Cycle Assessment (LCA) of the process applied to ruthenium and nickel reveals a remarkable environmental benefit. For ruthenium, emissions are reduced by over 99.6% compared to traditional mining. Even more impressive is the result for nickel: the SWaP process not only reduces emissions but becomes carbon negative, actively avoiding the total CO₂ production associated with conventional methods. ' Circular Materials strengthens its technological leadership and, together with its partners, builds a solid and integrated circular supply chain capable of transforming industrial waste into new resources, preventing the loss of critical materials,' says Marco Bersani, Founder & CEO of Circular Materials. ' With the industrial-scale recovery of ruthenium and nickel, we are shaping a strategy that reduces dependence on external sources, lowers the environmental impact of production processes, and valorizes waste streams that until now have been dispersed '. In a global context marked by the impacting scarcity of critical resources and the need to ensure a secure and sustainable supply, Circular Materials stands out as a key player in a new European industrial paradigm focused on recovering the resources the world needs most. About Us: Circular Materials Circular Materials is a groundbreaking company with proprietary technology for the recovery of strategic metals from industrial wastewater through a sustainable and highly efficient process. The company has developed and patented the Supercritical Water Precipitation (SWaP) technology, which simultaneously treats wastewater and recovers metal, eliminating toxic sludge production and significantly reducing environmental impact, both in terms of waste and emissions.
